| Revenue growth | Organic revenue up 13.7% FY26, beating the 13% guidance upper end. |
|---|---|
| Margins | EBITDA margin expanded 140bps to 25.9%, targeting 27-28% by FY28. |
| Demand visibility | Strong trends in specialized testing (Genomics) and wellness segments. |
| Management confidence | Confident, shifting from aggressive lab rollouts to throughput-led productivity. |
Growth
Organic revenue grew 13.7% in FY26, exceeding the guided 12-13%. Growth is healthy, split between 9.3% volume and 5% realization.
Outlook
Guided 14-15% revenue CAGR over three years with EBITDA margins reaching 27-28% by FY28.
Risks
Expansion of 'mini-hubs' increases capex risk; reliance on high-end genomics might face specialized competition.
Earnings Call filed with BSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹582.60
- Market cap
- ₹12,086 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 59.9×Sector 57.8×
- Promoter holding
- 48.86%-0.01% QoQ
- FII holding
- 11.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Employee Stock Options
Metropolis Healthcare allotted 66,312 equity shares to employees under its RSU Plan, 2020. This exercise follows the vesting of RSUs previously granted to staff.
Metropolis Healthcare Merger & Restructuring Worth ₹1.26 Cr
Metropolis Healthcare's subsidiary MQSPL will issue shares to Medsource and Dr. Puneet Kumar Nigam for ₹1.26 Crore, diluting MHL's stake to 54.90% through this strategic restructuring.
- Value
- ₹1.26 Cr
Metropolis Healthcare Capital Structure Change
Franklin Templeton Mutual Fund acquired 7,42,409 Metropolis Healthcare shares via open market, raising its stake to 5.10%. No transaction value was disclosed in the filing.
Metropolis Healthcare Earnings Call Transcript: Key Takeaways
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
- Call
- Guides 15% growth
Metropolis Healthcare Investor Presentation: Key Takeaways
Metropolis Healthcare reports strong Q1FY27 results with Revenue at INR 450 Cr (up 17% YoY) and EBITDA at INR 113 Cr (up 27% YoY).
- Call
- Guides 11% growth
Metropolis Healthcare Q1 FY27 Results: Net Profit ₹56.9 Cr, Up 25.9% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹450.2 Cr (+16.6% YoY) and net profit of ₹56.9 Cr (+25.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹56.9 Cr · +25.9% YoY